Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
<< anterior 21 a 40 de 305 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86. [Ref.ID 97034]
22.Enlace a cita original Cita con resumen
Moore AA. Good news about hormonal contraceptives in obese women. Journal Watch 2013:14 de marzo. [Ref.ID 96361]
23.Tiene citas relacionadas Cita con resumen
Hunt LP, Ben-Shlomo Y, Clark EM, Dieppe P, Judge A, MacGregor AJ, Tobias JH, Vernon K, Blom AW, on behalf of the National Joint Registry for England Wales and Northern Ireland. 90-day mortality after 409 096 total hip replacements for osteoarthritis, from the National Joint Registry for England and Wales: a retrospective analysis. Lancet 2013;382:1097-104. [Ref.ID 96311]
24.Tiene citas relacionadas
Weber MA, Bakris GL, Weir MR, Jamerson K. Obesity, blood pressure, and cardiovascular outcomes - Authors' reply. Lancet 2013;381:1982. [Ref.ID 95608]
25.Tiene citas relacionadas
Dong S, Mao B. Obesity, blood pressure, and cardiovascular outcomes. Lancet 2013;381:1982. [Ref.ID 95607]
26.Tiene citas relacionadas
Blankfield RP. Obesity, blood pressure, and cardiovascular outcomes. Lancet 2013;381:1981. [Ref.ID 95606]
27.Tiene citas relacionadas
Barrios V, Escobar C. Obesity, blood pressure, and cardiovascular outcomes. Lancet 2013;381:1981. [Ref.ID 95605]
28.Tiene citas relacionadas
Elijovich F, Laffer C. Obesity, blood pressure, and cardiovascular outcomes. Lancet 2013;381:1981. [Ref.ID 95604]
29.Tiene citas relacionadas Cita con resumen
Weber MA, Jamerson KB, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velázquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013;381:537-45. [Ref.ID 94952]
30.Tiene citas relacionadas
Messerli FH, Bangalore S. Diuretic-based regimens for obese patients?. Lancet 2013;381:512-3. [Ref.ID 94951]
31. Cita con resumen
Casazza K, Fontaine KR, Astrup A, Birch LL, Brown AW, Brown MMB, Durant N, Dutton G, Foster EM, Heymsfield SB, McIver K, Mehta T, Menachemi N, Newby PK, Pate R, Rolls BJ, Sen B, Smith Jr DL, Thomas DM, Allison DB. Myths, presumptions, and facts about obesity. N Engl J Med 2013;368:446. [Ref.ID 94822]
32. Cita con resumen
Cerdà D, Peris P, Monegal A, Albadalejo C, Surís X, Guañabens N. Identificación de las características clínicas y alteraciones analíticas asociadas a la fractura vertebral en mujeres con osteoporosis posmenopáusica. Med Clin (Barc) 2012;139:626-30. [Ref.ID 94299]
34. Cita con resumen
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB, Kigfield PD, Krumholz HM, Kwong RYK, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Sabik JF, Shaw LJ, Sikkema JD, Smith Jr CR, Smith Jr SC, Spertus JA, Williams SV. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;60:e44-e164. [Ref.ID 93287]
35.Enlace a cita original
Anónimo. Lorcaserín para el tratamiento de la obesidad: pocas ventajas con riesgos inciertos. ¿Sabía usted qué...? (4). CIMUN (Centro de Información de Medicamentos) 0:3 de septiembre. [Ref.ID 92927]
36. Cita con resumen
Jämsen E, Nevalainen P, Eskelinen A, Huotari K, Kalliovalkama J, Moilanen T. Obesity, diabetes, and preoperative hyperglycemia as predictors of periprosthetic joint infection: a single-center analysis of 7181 primary hip and knee replacements for osteoarthritis. J Bone Joint Surg Br 2012;94:e1011. [Ref.ID 92901]
37. Cita con resumen
Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, Gillespie C, Merritt R, Hu FB. Trends in cardiovascular health metrics and association with all-cause and CVD mortality among US adults. JAMA 2012;307:1273-83. [Ref.ID 92567]
38.
Watts G. The future of obesity treatment. BMJ 2012;344:20-1. [Ref.ID 92382]
39.Tiene citas relacionadas Cita con resumen
Vilsboll T, Christensen M, Junker AE, Knopf FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.. BMJ 2012;344:14. [Ref.ID 92292]
40.Tiene citas relacionadas Cita con resumen
Padwal R. Glucagon-like peptide-1 agonists. BMJ 2012;344:7. [Ref.ID 92290]
Seleccionar todas
 
<< anterior 21 a 40 de 305 siguiente >>